EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy

The selection of colorectal cancer patients for anti-epidermal growth factor receptor (EGFR) antibody therapy is based on the determination of their RAS mutation status—a strongly negative predictive factor—since the protein target, EGFR, is not a reliable predictor of therapeuti...

Full description

Bibliographic Details
Main Authors: Andrea Uhlyarik, Violetta Piurko, Zsuzsanna Papai, Erzsebet Raso, Erika Lahm, Edina Kiss, Marta Sikter, Jozsef Vachaja, Istvan Kenessey, Jozsef Timar
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
metastatic colorectal cancer
cetuximab
egfr protein
survival
Online Access:https://www.mdpi.com/2072-6694/12/3/614

Similar Items

Similar Items